SCM
ZYNE

Sio Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sio Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-70,300
Closed -$1.19M – 72
2017
Q2 		$1.19M Buy
+70,300
New +$1.4M 0.57% 45

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sio Capital Management's ZYNE Position: Q3 2017 in Review

Sio Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2017, closing a stake of 70,300 shares — an estimated $1.19M sold.

Sio Capital Management first reported a position in ZYNE in Q2 2017 and held it in 1 quarter. The position peaked at $1.19M in Q2 2017. 67 funds tracked by Wall St. Rank hold ZYNE as of Q3 2017.

  • Sio Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2017 after selling out during the quarter.
  • Sio Capital Management sold 70,300 Zynerba Pharmaceuticals, Inc shares in Q3 2017, an estimated $1.19M.
  • Sio Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 1 quarter.
  • Sio Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $1.19M in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2017.

Based on Sio Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.